{"id":99,"date":"2020-04-24T03:33:18","date_gmt":"2020-04-24T03:33:18","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=99"},"modified":"2020-05-12T05:32:33","modified_gmt":"2020-05-12T05:32:33","slug":"16-april-2020-ivermectin-use-requires-careful-risk-benefit-considerations","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/16-april-2020-ivermectin-use-requires-careful-risk-benefit-considerations\/","title":{"rendered":"(16 April 2020) Ivermectin- Use requires careful risk\u2013benefit considerations"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency<\/p>\n<p class=\"\">http:\/\/www.ajtmh.org\/content\/journals\/10.4269\/ajtmh.20-0271<\/p>\n<p class=\"\">Extreme due diligence and regulatory review are needed before testing ivermectin in severe disease for following 3 points,&nbsp;<\/p>\n<ol class=\"\">\n<li>Neurotoxicity<\/li>\n<li>Concurrent use of antiretrovirals<\/li>\n<li>Doses required to reach levels effective against SARS-CoV 2<\/li>\n<\/ol>\n<p class=\"\">&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency http:\/\/www.ajtmh.org\/content\/journals\/10.4269\/ajtmh.20-0271 Extreme due diligence and regulatory review are needed before testing ivermectin in severe disease for following 3 points,&nbsp; Neurotoxicity Concurrent use of antiretrovirals Doses required to reach&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/16-april-2020-ivermectin-use-requires-careful-risk-benefit-considerations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(16 April 2020) Ivermectin- Use requires careful risk\u2013benefit considerations&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,16,1],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/99"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=99"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/99\/revisions"}],"predecessor-version":[{"id":101,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/99\/revisions\/101"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=99"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=99"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=99"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}